Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
46.20
-3.28 (-6.63%)
At close: May 19, 2026, 4:00 PM EDT
46.20
0.00 (0.00%)
After-hours: May 19, 2026, 4:10 PM EDT
Nanobiotix Employees
Nanobiotix had 100 employees as of December 31, 2025. The number of employees decreased by 8 or -7.41% compared to the previous year.
Employees
100
Change (1Y)
-8
Growth (1Y)
-7.41%
Revenue / Employee
$382,682
Profits / Employee
-$281,331
Market Cap
2.16B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 100 | -8 | -7.41% | 100 | 0 |
| Dec 31, 2024 | 108 | 6 | 5.88% | 108 | 0 |
| Dec 31, 2023 | 102 | 0 | - | 102 | 0 |
| Dec 31, 2022 | 102 | 2 | 2.00% | 102 | 0 |
| Dec 31, 2021 | 100 | 10 | 11.11% | 100 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ultragenyx Pharmaceutical | 1,371 |
| Celldex Therapeutics | 198 |
| Relay Therapeutics | 192 |
| Immunome | 177 |
| Disc Medicine | 154 |
| IDEAYA Biosciences | 145 |
| Kodiak Sciences | 130 |
NBTX News
- 1 day ago - Nanobiotix price target raised to EUR 60 from EUR 34 at H.C. Wainwright - TheFly
- 1 day ago - Nanobiotix Phase 2 Lung Cancer Trial Shows 85.7% Response Rate - Nasdaq
- 2 days ago - Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - GlobeNewsWire
- 15 days ago - Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment - TheFly
- 15 days ago - Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study - GlobeNewsWire
- 18 days ago - Nanobiotix price target raised to $30 from $3.50 at UBS - TheFly
- 4 weeks ago - Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery - Nasdaq
- 4 weeks ago - Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology - GlobeNewsWire